Protection from lethal influenza virus challenge by oral type 1 interferon
MW Beilharz, JM Cummins, AL Bennett - Biochemical and biophysical …, 2007 - Elsevier
MW Beilharz, JM Cummins, AL Bennett
Biochemical and biophysical research communications, 2007•ElsevierThe persistence of highly pathogenic avian influenza within wild bird populations has forged
interest in control measures to limit a possible human pandemic. We therefore investigated
the efficacy of low dose oral administration of IFN-α as a potential therapy against influenza
infection in a murine model. We have identified an optimal low oral dose of IFN-α that when
delivered daily as prophylactic therapy protects C57BL/6J mice from a lethal challenge with
mouse adapted human influenza virus A/PR/8/34 (H1N1). These results provide strong …
interest in control measures to limit a possible human pandemic. We therefore investigated
the efficacy of low dose oral administration of IFN-α as a potential therapy against influenza
infection in a murine model. We have identified an optimal low oral dose of IFN-α that when
delivered daily as prophylactic therapy protects C57BL/6J mice from a lethal challenge with
mouse adapted human influenza virus A/PR/8/34 (H1N1). These results provide strong …
The persistence of highly pathogenic avian influenza within wild bird populations has forged interest in control measures to limit a possible human pandemic. We therefore investigated the efficacy of low dose oral administration of IFN-α as a potential therapy against influenza infection in a murine model. We have identified an optimal low oral dose of IFN-α that when delivered daily as prophylactic therapy protects C57BL/6J mice from a lethal challenge with mouse adapted human influenza virus A/PR/8/34 (H1N1). These results provide strong support for the application of low dose type 1 IFN pretreatment to human influenza control.
Elsevier
